Patent ID: 8802240

Claim:
A method for inducing radiosensitivity in normal cancer cells or radioresistant cancer cells comprising the steps of: providing cancer cells having at least one of normal cancer cells and radioresistant cancer cells; conjugating an anti-angiogenic thyroid hormone analog to a polymer via a linker; formulating the anti-angiogenic thyroid hormone analog into a nanoparticle; administering an effective amount of an anti-angiogenic thyroid hormone analog to a patient, wherein the anti-angiogenic thyroid hormone analog is selected from the group consisting of tetraiodothyroacetic acid (Tetrac), triiodothyroacetic acid (Triac), monoclonial antibody LM609, XT199 and combinations thereof, wherein the anti-angiogenic thyroid hormone analog acts exclusively at the cell surface receptor αVβ3; and irradiating the cancer cells with an external radiation source.